dormakaba Holding AG provides access and security solutions worldwide. It offers door hardware products, including door closers, locks, fittings, emergency exits, and panic hardware; interior glass systems comprising man…
Industry Peers
Building Products & Equipment| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
TThe Market – Analysen und Hintergründe aus der Wirtschaft | ||
 dormakaba Holding (VTX:DOKA) shareholders YoY returns are lagging the company's 20% three-year earnings growth It hasn't been the best quarter for dormakaba Holding AG ( VTX:DOKA ) shareholders, since the share price has fallen... | ||
dormakaba Holding AG (VTX:DOKA) most popular amongst retail investors who own 52% of the shares, institutions hold 43% Key Insights dormakaba Holding's significant retail investors ownership suggests that the key decisions are influenced... | ||
Returns On Capital Are A Standout For dormakaba Holding (VTX:DOKA) Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business... | ||
CComdirect | ||
There's A Lot To Like About dormakaba Holding's (VTX:DOKA) Upcoming CHF09.20 Dividend It looks like dormakaba Holding AG ( VTX:DOKA ) is about to go ex-dividend in the next four days. The ex-dividend date... | ||
dormakaba Holding AG (VTX:DOKA) Delivered A Better ROE Than Its Industry Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is... | ||
If EPS Growth Is Important To You, dormakaba Holding (VTX:DOKA) Presents An Opportunity Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks... | ||
 Heineken’s Strongbow adds NaviLens levels to packaging The cider brand has added a high-contrast NaviLens QR code to its cans. | ||
 3 firms to lay off hundreds of North Jersey-based employees BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty | ||
 Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
 Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
 dormakaba Holding Full Year 2025 Earnings: EPS Misses Expectations dormakaba Holding ( VTX:DOKA ) Full Year 2025 Results Key Financial Results Revenue: CHF2.87b (up 1.2% from FY 2024... | ||